Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth Portfolio agnostic to therapeutic area, modality and drug class Rare Disease Unique ability to invest in multiple products in the same class or TA Anti-TNFS Cardiology XXXIIX Hematology ~35 Approved products (1) Diabetes ® HUMIRA Immunology Neurology Remicade Cimzia Migraine Nurtec™ODT Emgality. Multiple sclerosis TYSABRI Prostate cancer Oncology Erleada ROYALTY PHARMA TA: therapeutic area 1. Royalty Pharma portfolio also includes 10 development-stage therapies. Tecfidera Xtandi. 20

View entire presentation